Reading COR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track COR free→Reading COR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track COR free→QuarterlyIQ Insights · COR
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 15, 2026, Cencora, Inc. (the “Company”) announced that Silvana Battaglia will retire as Executive Vice President and Chief Human Resources Officer of the Company effective July 12, 2026. Ms. Battaglia will serve in an advisory capacity through the end of 2026. Ms. Battaglia’s decision to retire from her position was not the result of a disa…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 27, 2026, Cencora, Inc. (the “Company”) announced that Eva C. Boratto has been appointed Executive Vice President and Chief Financial Officer of the Company (the “Appointment”), effective June 29, 2026 (the “Effective Date”). Ms. Boratto succeeds James F. Cleary, who will be retiring from his role as Executive Vice President and Chief Financ…
of the August 2024 8-K is incorporated herein by reference. The foregoing summaries of the Employment Agreement, Indemnification Agreement, and Sign-on Bonus Reimbursement Agreement are qualified in their entireties by reference to the full text of each agreement, which are Exhibit 10.1, Exhibit 10.2 and Exhibit 10.3, respectively, to this Current Report on Form 8-K (“Current Report”) and incorporated herein by reference.
of this Current Report, including Exhibit 99.1 hereto, is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by…
Results of Operations and Financial Condition. On May 6, 2026, Cencora, Inc. (the “Company”) issued a news release announcing the Company’s earnings for the fiscal quarter ended March 31, 2026. A copy of the news release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Current Report, including the exhibit attached hereto as Exhibit 99.1 and the information under
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 17, 2026, Cencora, Inc. (the “Company”) announced that James F. Cleary will retire as Executive Vice President and Chief Financial Officer of the Company effective June 30, 2026. Mr. Cleary’s decision to retire from his position was not the result of a disagreement on any matter related to the Company’s operations, policies or practices.
Entry into a Material Definitive Agreement. On February 13, 2026, Cencora, Inc. (the “Company”) completed the sale of $3.0 billion aggregate principal amount of the Company’s Senior Notes as follows: $500,000,000 aggregate principal amount of the Company’s 3.950% Senior Notes due 2029 (the “2029 Notes”), $500,000,000 aggregate principal amount of the Company’s 4.250% Senior Notes due 2030 (the “2030 Notes”), $500,000,000 aggregate principal amount of the Company’s 4.600% Senior Notes due 2033…
Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
Other Events. On February 10, 2026, the Company entered into an Underwriting Agreement (the “Underwriting Agreement”), by and among the Company, Citigroup Global Markets Inc., J.P. Morgan Securities LLC, BofA Securities, Inc. and Wells Fargo Securities, LLC on behalf of themselves and as representatives of the several underwriters named therein (the “Underwriters”). The Underwriting Agreement provides for the issuance and sale by the Company, and the purchase by the Underwriters, of the Notes…
Regulation FD Disclosure. On February 10, 2026, Cencora, Inc. (the “Company” or “Cencora”) issued a news release announcing that it priced $500,000,000 aggregate principal amount of the Company’s 3.950% Senior Notes due 2029 (the “2029 Notes”), $500,000,000 aggregate principal amount of the Company’s 4.250% Senior Notes due 2030 (the “2030 Notes”), $500,000,000 aggregate principal amount of the Company’s 4.600% Senior Notes due 2033 (the “2033 Notes”), $1,000,000,000 aggregate principal amoun…
Other Events. Cencora, Inc. (the “Company”) is filing this Current Report on Form 8-K (this “Form 8-K”) to reflect a revision to the presentation of its financial information as set forth in its Annual Report on Form 10-K for the fiscal year ended September 30, 2025 (the “2025 Form 10-K”), as filed with the Securities and Exchange Commission (“SEC”) on November 25, 2025, to give effect to a change in its segment reporting. As previously disclosed, the Company undertook a strategic review of i…
Results of Operations and Financial Condition. On February 4, 2026 Cencora, Inc. (the “Company”) issued a news release announcing the Company’s earnings for the fiscal quarter ended December 31, 2025. A copy of the news release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Current Report, including the exhibit attached hereto as Exhibit 99.1 and the information under
Regulation FD Disclosure. On February 2, 2026, the Company acquired the majority of the outstanding equity interests that it did not previously own in OneOncology, a physician-led national platform empowering independent medical specialty practices rooted in oncology for a total cash consideration of approximately $4.6 billion. OneOncology’s affiliated practices and management retained a minority interest in OneOncology. The Company funded the transaction through new debt financing. OneOncolo…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Director Appointment On January 20, 2026, the Board of Directors (the “Board”) of Cencora, Inc. (the “Company”) appointed Ellen G. Cooper to serve on the Board (the “Appointment”), effective immediately. In connection with the Appointment, the Board increased from ten to eleven members in accordance with the Company’s Amended and Restated Bylaws. M…
Entry into a Material Definitive Agreement. Amendment to Revolving Credit Facility On January 12, 2026, Cencora, Inc. (the “Company”) entered into an Incremental Facility and Amendment Agreement (the “Amendment”) to that certain Amended and Restated Credit Agreement (as amended by the Amendment, the “Revolving Credit Agreement”), dated as of June 4, 2025, among the Company, the borrowing subsidiaries party thereto, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative age…
Creation of Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
Results of Operations and Financial Condition. Earnings Release for the Fiscal Quarter and Year Ended September 30, 2025 On November 5, 2025, Cencora, Inc. (the “Company”) issued a news release announcing the Company’s earnings for the fiscal quarter and year ended September 30, 2025. A copy of the news release is attached hereto as Exhibit 99.1 and incorporated herein by reference. New Reporting Structure Recently, Cencora undertook a strategic review of its business to ensure alignment with…
Entry into a Material Definitive Agreement. Amendment of Term Loan On September 5, 2025, Cencora, Inc. (the “Company”) entered into Amendment No. 2 (the “Term Credit Amendment”) to the Term Credit Agreement, dated as of November 26, 2024, among the Company, the lenders party thereto and Bank of America, N.A., as administrative agent, as amended by Amendment No. 1, dated as of June 4, 2025 (the “Term Credit Agreement”, as amended by the Term Credit Amendment, the “Amended Term Credit Agreement…
Other Events. On September 3, 2025, Cencora, Inc., a Delaware corporation (the “Company”), announced an agreement, subject to court approval, that would resolve the stockholder derivative action captioned Lebanon County Employees’ Retirement Fund v. Steven H. Collis et al. , C.A. No. 2021-1118-JTL (the “Action”). As the Company has previously disclosed, on December 30, 2021, the Lebanon County Employees’ Retirement Fund and Teamsters Local 443 Health Services & Insurance Plan (the “Plaintiffs…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 27, 2025, Cencora, Inc. (the “Company”) announced that its Board of Directors (the “Board”) has appointed D. Mark Durcan as Chairman of the Board, effective October 1, 2025. Mr. Durcan has served as a director of the Company since September 2015 and as the Board’s Lead Independent Director since March 2023. Mr. Durcan will succeed Steven…
Results of Operations and Financial Condition. On August 6, 2025, Cencora, Inc. (the “Company”) issued a news release announcing the Company’s earnings for the fiscal quarter ended June 30, 2025. A copy of the news release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Current Report, including the exhibit attached hereto as Exhibit 99.1 and the information under
Entry into a Material Definitive Agreement. Amendment of Securitization Facility On June 30, 2025, subsidiaries of Cencora, Inc. (the “Company”) entered into a Twenty-Second Amendment to Amended and Restated Receivables Purchase Agreement (the “Receivables Amendment”), among AmeriSource Receivables Financial Corporation (“ARFC”), as seller, AmerisourceBergen Drug Corporation (“ABDC”), as servicer, the Purchaser Agents and Purchasers party thereto, and MUFG Bank, Ltd., as administrator. The Re…
Creation of Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
Entry into a Material Definitive Agreement. Amendment and Restatement of Revolving Credit Facility On June 4, 2025, Cencora, Inc. (the “Company”) and its subsidiaries BP Pharmaceuticals Laboratories Unlimited Company and Innomar Strategies Inc. entered into an Amended and Restated Credit Agreement (the “Amended and Restated Credit Agreement”) to amend and restate the Amended and Restated Credit Agreement, dated as of October 9, 2024, among the Company, the borrowing subsidiaries party thereto…
Creation of Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.